Radioiodinated_1-(5-iodo-5-deoxy-beta-D-arabinofuranosyl)-2-nitroimidazole_(iodoazomycin_arabinoside:_IAZA):_a_novel_marker_of_tissue_hypoxia._1-(5-Iodo-5-deoxy-beta-D-arabinofuranosyl)-2-nitroimidazole_(IAZA)_has_been_synthesised_and_labeled_with_125I._Radioiodinated_IAZA_was_shown_to_undergo_hypoxia-dependent_binding_in_EMT-6_cells_in_vitro_and_to_have_an_initial_binding_rate_of_284_pmole/10(6)_cells/hr_at_a_substrate_concentration_of_30_microM._This_binding_rate_is_more_than_three_times_that_of_the_reference_compound,_misonidazole_(89_pmole/10(6)_cells/hr)._The_elevated_binding_rate_was_accompanied_by_in_vitro_cytotoxicity_30-40_times_greater_than_that_observed_for_misonidazole._Whole-body_elimination_and_biodistribution_studies_in_BALB/c_mice_bearing_implanted,_subcutaneous_EMT-6_tumors_showed_a_rapid_excretion_(greater_than_98%_in_24_hr)_with_moderate_tissue_levels_which,_in_general,_declined_as_a_function_of_blood_clearance._Tumor-to-blood_ratios_of_4.6_(4_hr)_and_8.7_(8_hr),_with_respective_tumor_uptake_values_of_2.08%_and_1.22%_ID/g_of_tissue,_form_a_rational_basis_for_evaluation_of_this_and_related_2-nitroimidazole_analogs_as_radiopharmaceuticals_suitable_for_scintigraphic_evaluation_of_tissue_(tumor)_hypoxia.